Fair Value Measurements

12 Months Ended

Dec. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements:

ASC 820-10 Fair Value Measurements and Disclosures defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets and liabilities. Active market means a market in which transactions for assets or liabilities occur with “sufficient frequency” and volume to provide pricing information on an ongoing unadjusted basis. Cash equivalents include highly liquid investments with an original maturity of three months or less at acquisition. We have determined that our cash equivalents in their entirety are classified as Level 1 within the fair value hierarchy.

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets primarily include debt securities, including corporate bonds with quoted prices that are traded less frequently than exchange-traded instruments. All of our Level 2 asset values are determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The pricing model information is provided by third party entities (e.g., banks or brokers). In some instances, these third party entities engage external pricing services to estimate the fair value of these securities. We have a general understanding of the methodologies employed by the pricing services in their pricing models. We corroborate the estimates of non-binding quotes from the third party entities’ pricing services to an independent source that provides quoted market prices from broker or dealer quotations. We investigate large differences, if any. Based on historical differences, we have not been required to adjust quotes provided by the third party entities’ pricing services used in estimating the fair value of these securities.

Level 3: Unobservable inputs that are not corroborated by market data.

Financial assets and liabilities

The fair value of our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 were as follows ($ amounts in thousands):

	Estimated Fair Value at
	December 31, 2013		Level 1		Level 2		Level 3
	(Successor)
Corporate bonds (Note 6)		$3,541		$—		$3,541		$—
Cash equivalents		$66,782		$66,782		$—		$—
Senior secured term loan (Note 13)		$1,063,255		$—		$1,063,255		$—
7.375% senior notes (Note 13)		$507,150		$—		$507,150		$—
Derivative instruments - Interest rate caps (Note 14)		$1,189		$—	$	1,189		$—

The fair value of our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2012 were as follows ($ amounts in thousands):

	Estimated Fair Value at
	December 31, 2012		Level 1		Level 2		Level 3
	(Successor)
Corporate bonds (Note 6)		$11,727		$—		$11,727		$—
Cash equivalents		$14,370		$14,370		$—		$—
Senior secured term loan (Note 13)		$1,052,363		$—		$1,052,363		$—
7.375% senior notes (Note 13)		$484,488		$—		$484,488		$—

The carrying amount reported in the consolidated balance sheets for accounts receivables, net, inventories, prepaid expenses and other current assets, accounts payable, payables due to distribution agreement partners, accrued salaries and employee benefits, accrued government pricing liabilities, accrued legal fees, accrued legal settlements, payable to former Anchen securityholders, and accrued expenses and other current liabilities approximate fair value because of their short-term nature.

    As noted in Note 4, “Edict Acquisition”, we had contingent purchase price liabilities that represented subsequent milestone payments related to successful FDA inspection of the Par Formulations manufacturing facility and ANDA filings. Through December 31, 2013 we had paid the total $11,641 thousand of contingent purchase price liabilities.

Non-financial assets and liabilities

The Company does not have any non-financial assets or liabilities as of December 31, 2013 or December 31, 2012 that are measured in the consolidated financial statements at fair value.

Intangible Assets

We evaluate long-lived assets, including intangible assets with definite lives, for impairment periodically or whenever events or other changes in circumstances indicate that the carrying value of an asset may no longer be recoverable. If such circumstances are determined to exist, projected undiscounted future cash flows to be generated by the long-lived asset or the appropriate grouping of assets (level 3 inputs), is compared, at its lowest level of identifiable cash flows, to the carrying value to determine whether impairment exists. During the period from January 1, 2012 to September 28, 2012 (Predecessor), we abandoned an in-process research and development project and exited the market of a commercial product. As a result, we recorded an intangible asset impairment of $5,700 thousand. Both of these intangible assets had been acquired in the Anchen Acquisition. In the year ended December 31, 2013, we adjusted our forecast for certain products to reflect competition and pricing assumptions which caused us to assess the carrying value of certain intangible assets. We adjusted the carrying value to the calculated discounted cash flows of 6 identified products and recorded an intangible asset impairment charge of $39,946 thousand. In connection with our valuation of goodwill and other indefinite-lived intangible assets, we adjusted the carrying value of 3 identified intangible assets and recorded an intangible asset impairment charge totaling $60,147 thousand. Our total definite-lived and indefinite-lived intangible asset impairment charge for the year ended December 31, 2013 was $100,093 thousand.

Derivative Instruments - Interest Rate Caps

We use interest rate cap agreements to manage our interest rate risk on our variable rate long-term debt. Refer to Note 14, "Derivatives Instruments and Hedging Activities," for further information.